SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer

JISHENG BAO1, LIPING ZHU2, QI ZHU2, JIANHUA SU1, MENGLAN LIU1 and WEI HUANG1

Departments of 1Geriatrics and 2Internal Medicine, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, Jiangsu 214002, P.R. China

Received May 18, 2015; Accepted June 29, 2016

DOI: 10.3892/ol.2016.4988

Abstract. Re-programming of lipogenic signaling has been previously demonstrated to result in significant alterations in tumor cell pathology. Sterol regulatory element-binding protein 1 (SREBP-1) is a known transcription factor of lipogenic genes. Despite the fact that its functions in proliferation and apoptosis have been elucidated in recent studies, its role in tumor cell migration and invasion, particularly in breast cancer, remains unclear. In present study, the messenger RNA and protein expression levels of SREBP-1 in cancer tissues were observed to be overexpressed compared with those in matched para-cancerous tissues (P<0.01). SREBP-1 level was highly positively correlated with tumor differentiation (P<0.001), tumor-node-metastasis stage (P=0.044) and lymph node metastasis (P<0.001). High expression of SREBP-1 predicted poor prognosis in patients with breast cancer. Additionally, multivariate analysis revealed that SREBP-1 was an independent factor of 5-year overall and disease-specific survival in breast cancer patients (P<0.01). In vitro studies revealed that the suppression of SREBP-1 expression in both MDA-MB-231 and MCF7 cells significantly inhibited cell migration and invasion (P<0.01). The present data indicate that SREBP-1 plays a critical role in breast cancer migration and invasion, and may serve as a prognostic marker of this malignancy.

Introduction

Breast cancer is the most common malignant cancer and the major cause of mortality due to cancer in females worldwide (1), and the morbidity has increased gradually over recent years (2). Although the tremendous progress in diagnostic instruments and the development of standardized systematic therapy, including various combinations of surgery, radiation therapy, chemotherapy and hormone therapy (3), the prognosis for breast cancer patients is still not ideal. The high mortality rate is associated with the ability of breast cancer cells to metastasize to distant organs (4). Metastasis is a multistep process requiring cellular and environmental progresses to a secondary site (5). However, the regulatory mechanisms remain poorly understood. Therefore, the identification of critical pathways will help to discover novel therapeutic targets for breast cancer.

Increased evidence suggests that the lipogenic phenotype is a major characteristic of cancer (6,7). Current research links aberrant lipogenesis and cholesterogenesis with breast cancer development and progression (8). Sterol regulatory element-binding proteins (SREBPs) are important in regulating the gene expression of key enzymes involved in fatty acid and cholesterol biosynthesis (9,10), including SREBP-1a, SREBP-1c and SREBP-2. Previous studies have demonstrated that the aberrant expression of SREBP-1 is upregulated in several metabolic diseases, including diabetes mellitus, morbid obesity, hyperlipidemia and atherosclerosis (11). In addition to regulation by sterols, SREBP-1 has been reported to be stabilized and activated by the phosphatidylinositol-4,5-bisphosphate 3-kinase/Akt oncogenic signaling pathway in cancer (12-14). The suppressed expression of SREBP-1 could inhibit cell growth, migration and invasion, and induce cell apoptosis in ovarian cancer (15). Pharmacological and genetic inhibition or reduction of SREBP-1 significantly induced glioblastoma cell death (16). Overexpression of SREBP-1 has been observed in atypically hyperplastic endometrium and endometrial cancer tissues, while knockdown of SREBP-1 dramatically inhibited the proliferating potential of endometrial cancer cells (17). The expression level of SREBP-1 is also elevated in certain types of tumors such as prostate and gastric cancer (18,19). However, the expression and function of SREBP-1 in human breast cancer remains to be fully elucidated.

In the present study, the expression levels SREBP-1 in breast cancer tissues were evaluated. The data indicated that the SREBP-1 level was correlated with prognosis of breast cancer, and suggested that it may serve as an independent prognostic factor in breast cancer. SREBP-1 promoted cell migration and invasion in vitro. Taken together, the present results demonstrated that SREBP-1 is pivotal for the tumorigenesis of breast cancer.
Materials and methods

Ethical review. The Ethics Committee of Nanjing Medical University Affiliated Wuxi Second Hospital (Wuxi, Jiangsu, China) approved the current protocols, according to the 1975 Declaration of Helsinki. Informed consent form was signed by each patient.

Clinical tissue specimens and cell lines. The 82 female patients enrolled in the present study underwent curative surgery for breast cancer without radiation or chemotherapy prior to surgical treatment at the Nanjing Medical University Affiliated Wuxi Second Hospital, between January 2008 and December 2009. The mean age of the patients was 54.8 years (standard error of the mean, 3.2; range, 29-73 years). Tissue specimens were confirmed separately by two experienced pathologists under double-blinded conditions, and none of the patients received any therapy prior to operation. The demographic features and clinicopathological data were reviewed in the patients' medical records. The specimens were collected and immediately stored in 4% paraformaldehyde for immunohistochemistry (IHC), or in liquid nitrogen for western blotting. The prognosis concerning disease-specific survival and overall survival, which were defined as the time from surgery to first recurrence or mortality, respectively, were analyzed. A total of 60 months of clinical follow-up data were available.

The human breast cancer cell lines MCF7 and SKBR3 were cultured in complete Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), while the human breast cancer cell line MDA-MB-231 was cultured in L15 medium (Invitrogen; Thermo Fisher Scientific, Inc.) containing 10% FBS, in a humidified 5% CO2 incubator at 37°C. The cell lines were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China).

IHC staining. Paraformaldehyde-fixed, paraffin-embedded tissue sections were used for IHC with an anti-SREBP-1 (1:500; catalog no. sc-8984; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) antibody, according to the streptavidin-peroxidase method (15). The staining results for the SREBP-1 protein were evaluated by the staining intensity and the percentage of positive cells. The staining intensity was scored as follows: 0=none; 1=weak; 2=moderate; and 3=strong. The percentage of positive cells was scored as follows: 0, <5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; and 4, >75%. A total of 10 independent, high-magnification (x400) fields were observed to calculate a mean score. A total score >1 was defined as positive staining.

Small interfering (si)RNA transfection. siRNA specific against SREBP-1 and non-silencing scrambled sequence siRNA (used as the negative control) were synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used for transfection in accordance with the manufacturer's protocol. Further experiments were performed after 48 h. The specific SREBP-1 siRNA sequence was: Sense 5'-GGAAGAGUCAGU GCCACUGT-3' and anti-sense 5'-CAGUGCACUGACUC UUCCTT-3'.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA was extracted from breast cancer tissues and cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. RNA concentration was quantified by a NanoDrop spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, DE, USA). Complementary (c)DNA was synthesized using a first-strand cDNA synthesis kit (GE Healthcare Life Sciences; Chalfont, UK). cDNA (2 µl) was amplified and quantified by RT-qPCR using SYBR Premix Ex Taq II (Takara Biotechnology Co., Ltd., Dalian, China) with the following cycling conditions: 94°C for 3 min, followed by 35 cycles of 94°C for 30 sec and 60°C for 30 sec. The human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was regarded as the internal control. The primers used for PCR were synthesized by Shanghai GenePharma Co., Ltd., and their sequences were as follows: 5'-CAGTCACCTTGGAGGATA-3' (forward) and 5'-CAAAGATTGCGGTAGAC-3' (reverse) for SREBP-1, and 5'-CAAGCTATTTCCGTATGAC-3' (forward) and 5'-CAGTGGAGCTCTCTCTCTCC-3' (reverse) for GAPDH. All samples were normalized to GAPDH and calculated with the relative 2-ΔΔCq method (17).

Protein extraction and western blotting. A modified radioimmunoprecipitation assay buffer with protease inhibitor was used for protein isolation (Sigma-Aldrich, St. Louis, MO, USA). Protein concentrations were measured using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Inc., Rockford, IL, USA). Total proteins (50 µg) were resolved on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA), which were blocked with 5% non-fat dry milk (Bio-Rad Laboratories, Inc., Hercules, CA, USA) in phosphate-buffered saline (PBS) with 0.1% Tween 20. Next, the membranes were incubated with primary anti-SREBP-1 (1:300; catalog no. sc-365513; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and anti-β-actin (1:5,000; catalog no. 3700; Cell Signaling Technology, Inc.) antibodies at 4°C overnight, followed by horseradish peroxidase-conjugated secondary antibodies (1:5,000; catalog no. bs12471; Bioworld Technology, Inc., St. Louis Park, MN, USA) for 2 h at room temperature. Bands were detected with an enhanced chemiluminescence reagent (EMD Millipore).

Wound healing assay. Cells (5x10^4 cells/well) were seeded into a 6-well plate and incubated to a confluent monolayer. Scratch wounds were created using a pipette tip, and washed twice with sterile PBS. Cells were then cultured in serum-free medium in a humidified 5% CO2 incubator at 37°C for 48 h, and visualized under an inverted microscope.

Transwell assay. Transwell chambers (8 µm pore-sized; Nalge Nunc International; Thermo Fisher Scientific, Inc.) were coated with matrigel (BD Biosciences, Franklin Lakes, NJ, USA) at 1 mg/ml on the inner layer. Cells transfected with control siRNA or SREBP-1 siRNA were seeded in the upper chamber at a density of 1x10^5 cells/chamber in 100 µl serum-free medium. The lower chamber was filled with 600 µl DMEM containing 10% FBS. Plates were incubated for 24 h.
at 37°C, and cells in the top surface of the matrigel membrane were swabbed carefully. The adherent cells on the underside of the insert were stained with 0.3% crystal violet and counted under a light microscope. A total of four fields were randomly selected to calculate the mean cell number.

Statistical analysis. All data are presented as the mean ± standard deviation. SPSS version 13 (SPSS, Inc., Chicago, IL, USA) was used for Pearson χ² test and multivariate Cox regression analysis. Two-tailed Student’s t test or Kaplan-Meier method was used to calculate the survival, and log-rank test or analysis of variance was used to analyze the difference in multivariate Cox regression using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Increased SREBP-1 protein expression in breast cancer and its correlation with clinicopathological features. To evaluate the potential role of SREBP-1 in human breast cancer, RT-qPCR, IHC staining and western blotting were performed to investigate SREBP-1 messenger (m)RNA and protein expression in tissue samples of 82 patients with primary breast cancer, together with matched para-cancerous tissue samples. Notably, the SREBP-1 mRNA and protein level was robustly increased in the majority of the cancer samples compared

---

Table I. Correlation between relative SREBP-1 expression level and clinicopathological parameters in breast cancer (n=82).

| Clinical parameters | Cases (n) | Positive (n=58) | Negative (n=24) | P-value |
|---------------------|-----------|----------------|----------------|---------|
| Age (years)         |           |                |                |         |
| <50                 | 50        | 39             | 11             | 0.071   |
| ≥50                 | 32        | 19             | 13             |         |
| Tumor size (cm)     |           |                |                |         |
| <2                  | 39        | 27             | 12             | 0.776   |
| ≥2                  | 43        | 31             | 12             |         |
| Tumor location      |           |                |                |         |
| Left                | 44        | 31             | 13             | 0.953   |
| Right               | 38        | 27             | 11             |         |
| Differentiation     |           |                |                | <0.001* |
| Moderate/high       | 34        | 11             | 23             |         |
| Poor                | 48        | 47             | 1              |         |
| T stage             |           |                |                | 0.806   |
| I/II                | 67        | 47             | 20             |         |
| III/IV              | 15        | 11             | 4              |         |
| Lymph node metastasis |       |                |                | <0.001* |
| Negative            | 29        | 6              | 23             |         |
| Positive            | 53        | 52             | 1              |         |
| TNM stage           |           |                |                | 0.044*  |
| I/II                | 55        | 35             | 20             |         |
| III/IV              | 27        | 23             | 4              |         |
| ER status           |           |                |                | 0.585   |
| Negative            | 44        | 30             | 14             |         |
| Positive            | 38        | 28             | 10             |         |
| HER2 status         |           |                |                | 0.161   |
| Negative            | 38        | 24             | 14             |         |
| Positive            | 44        | 34             | 10             |         |
| PR status           |           |                |                | 0.866   |
| Negative            | 49        | 35             | 14             |         |
| Positive            | 33        | 23             | 10             |         |

*P<0.05. SREBP-1, sterol regulatory element-binding protein 1; TNM, tumor-node-metastasis; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
with para-cancerous tissues (P<0.01; Fig. 1A and B). SREBP-1 was positively stained in both the nucleus and the cytoplasm. Compared with malignant cells, SREBP-1 immunostaining in benign cells was negative or relatively weak (Fig. 1A). According to the criteria of semi-quantitative assessment employed, SREBP-1 was highly expressed in 58 (70.7%) of 82 breast cancers and in 24 (29.3%) of 82 para-cancerous tissues. Statistical analysis of SREBP-1 staining scores confirmed increased staining in malignant cells compared with benign cells (P<0.01; Fig. 1A). Western blotting further confirmed the IHC results (P<0.01; Fig. 1C).

Next, the association between the expression of SREBP-1 protein and clinicopathological features was analyzed (Table I). Pearson χ² test suggested that high SREBP-1 expression was strongly correlated with tumor differentiation, tumor-node-metastasis (TNM) stage and lymph node metastasis (P<0.01). However, there was no significant association between SREBP-1 expression and other clinicopathological variables. Taken together, these data reveal that the expression of SREBP-1 in breast cancer is elevated, and increased SREBP-1 expression is correlated with poor clinicopathological features in breast cancer.

Table II. Multivariate Cox regression analysis on 5-year overall and disease-specific survival of 82 breast cancer patients.

| Variables                      | Overall survival |                      | Disease-specific survival |                      |
|--------------------------------|------------------|----------------------|---------------------------|----------------------|
|                                | HR               | 95% CI               | P-value                   | HR                   | 95% CI               | P-value                   |
| SREBP-1                        | 2.976            | 1.109-7.987          | 0.030                     | 2.327                | 1.093-4.955          | 0.029                     |
| Age                            | 0.993            | 0.741-1.352          | 0.836                     | 0.854                | 0.651-1.223          | 0.885                     |
| Tumor size                     | 2.731            | 1.945-3.786          | 0.003                     | 2.912                | 1.883-4.147          | 0.001                     |
| Lymph node metastasis          | 3.183            | 1.991-4.505          | 0.001                     | 3.962                | 2.975-4.756          | <0.001                    |
| Histology grade                | 1.842            | 1.185-2.846          | 0.023                     | 1.954                | 1.512-2.513          | 0.032                     |

HR, hazard ratio; CI, confidence interval; SREBP-1, sterol regulatory element-binding protein 1.

Figure 1. SREBP-1 expression in breast cancer cases. (A) Representative immunostaining of SREBP-1 in tissues and immunohistochemistry scores: Left, positive expression of SREBP-1; right, negative expression of SREBP-1 (original magnification, x400). Expression of SREBP-1 (B) messenger RNA and (C) protein in breast cancer and para-cancerous tissues (n=82). Values are depicted as the mean ± standard deviation. SREBP-1, sterol regulatory element-binding protein 1; IHC, immunohistochemistry; N, normal; Ca, cancer; mRNA, messenger RNA.
High SREBP-1 expression correlates with a poor 5-year survival for breast cancer patients. To determine the role of SREBP-1 in predicting the prognosis of patients, Kaplan-Meier survival curves were constructed using 5-year overall and disease-specific survival to analyze cases with high and low SREBP-1 expression (n=82; follow-up time, 60 months). The results indicate that high SREBP-1 staining predicts a poor overall and disease-specific patient survival (P<0.01, log-rank test; Fig. 2A and B).

In addition, SREBP-1 was an independent prognostic marker for both 5-year overall survival (hazard ratio, 2.976; 95% confidence interval (CI), 1.109-7.987; P=0.030; Table II) and disease-specific survival (hazard ratio, 2.327; 95% CI, 1.093-4.955; P=0.029; Table II) according to multivariate Cox regression analysis. These results definitely confirmed that high SREBP-1 expression is associated with poor prognosis, suggesting that SREBP-1 may function as a prognostic marker for breast cancer.
SREBP-1 knockdown is established in breast cancer cell lines. In order to identify the function of SREBP-1, the SREBP-1 mRNA and protein levels were analyzed in three different breast cancer cell lines. Consistent with the clinical results, the expression levels of SREBP-1 were significantly higher in MCF7 and MDA-MB-231 cells than in SKBR3 cells (Fig. 3A and B). Based on such difference in SREBP-1 expression, MCF7 and MDA-MB-231 cells were selected, and SREBP-1 was knocked down by transfecting specific SREBP-1 siRNA into these cells. The RT-qPCR and western blotting results demonstrated that SREBP-1 was markedly downregulated by SREBP-1 siRNA in these cell lines (Fig. 3C and D).

Effect of SREBP-1 knockdown on the invasion and migration of breast cancer cells. To elucidate effect of SREBP-1 knockdown on breast cancer cell migration and invasion, mechanical scrape wound healing and transwell assays were performed. The wound healing assay revealed that the loss of SREBP-1 expression could significantly reduce the migration rate in both MDA-MB-231 and MCF7 breast cancer cells (P<0.01; Fig. 4A and B, respectively). Consistently, the transwell assay also confirmed that the cell migration rate was significantly decreased by SREBP-1 knockdown in these cells (P<0.01; Fig. 5A). Furthermore, compared with those in the control groups, the number of invaded cells in the SREBP-1 siRNA group was significantly reduced (P<0.01; Fig. 5B). These data, therefore, indicate that SREBP-1 has an impact on the migration and invasion of breast cancer cells.

Discussion

Numerous types of cancer exhibit increased de novo lipogenesis irrespective of the extracellular lipid availability (20). Exacerbated lipogenesis has been demonstrated to be one of main characteristics of cancer (19). The maintenance of intracellular lipid homeostasis depends on the balance between lipid biosynthesis and degradation (21). The upregulated lipogenesis in tumor cells is reflected by a marked increase in lipogenic enzymes, which is partly...
due to the transcriptional activation mediated by SREBP-1 in cancer cells (6,21). Consistent with the fundamental role of SREBP-1 in regulating multiple types of cancer, elevated SREBP-1 expression had a great impact on cancer progression and metastasis (22,23). However, the impact of SREBP-1 on the progression of breast cancer remains largely unknown, and the underlying mechanisms require to be elucidated.

The present study demonstrated that both the mRNA and protein levels of SREBP-1 were significantly overexpressed in breast cancer tissues compared with para-cancer tissues. In addition, upregulated SREBP-1 expression was highly correlated with tumor differentiation, TNM stage and lymph node metastasis. Kaplan-Meier analysis revealed that breast cancer patients with SREBP-1 positive expression had a poorer survival following surgery than those without SREBP-1 expression. These findings are consistent with previous data reporting that the level of SREBP-1 is associated with the tumorigenesis and prognosis of cancer (24). Additionally, the Cox proportional hazards model employed in the present study revealed that SREBP-1 was an independent factor for predicting the 5-year survival of patients. Therefore, these
results demonstrate that SREBP-1 is a critical molecule for prognosis determination in breast cancer.

To investigate the pathological function of SREBP-1 in breast cancer, several biophysical experiments were further conducted in SREBP-1-silenced cell lines, which were established by being transfected with specific siRNA targeting SREBP-1. The results revealed that SREBP-1 knockdown in breast cancer cells restrained cell migration and invasion, which are the cytological fundament of tumor metastasis. Previous studies have reported that the downregulation of SREBP-1 induces a decrease in the expression of several enzymes in the fatty acids signaling pathways, including acetyl-CoA carboxylase, fatty-acid synthase and stearoyl-CoA desaturase 1, which are involved in lipid metabolism, lipogenesis, proliferation, apoptosis and survival in breast cancer (25,26). Through approaches of either siRNA or small molecule inhibitors, depletion of the expression and activity of these genes suppressed tumor cell proliferation and growth (27,28). Therefore, SREBP-1 may be important in tumorigenesis via these molecular signaling pathways.

In conclusion, the present study found that SREBP-1 is upregulated in breast cancer tissues and cells, and that its elevated expression is associated with poor prognostic features. The in vitro studies indicated that SREBP-1 knockdown inhibits breast cancer cell migration and invasion. Therefore, SREBP-1 has the potential to be a valuable diagnostic and prognostic biomarker for breast cancer.

Acknowledgements

The present study was supported by Nanjing Medical University Affiliated Wuxi Second Hospital (Wuxi, China; grant no. 2014K-12).

References

1. Siegel R, Naishadhnam D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y and Hortobagyi GN: Is breast cancer survival improving? Cancer 100: 44-52, 2004.
3. Hurvitz SA, Hu Y, O'Brien N and Finn RS: Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 39: 219-229, 2013.
4. Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F and Polyak K: Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 74: 1338-1348, 2014.
5. Chen J and Gallo KA: MLK3 regulates paxillin phosphorylation in chemokine-mediated breast cancer cell migration and invasion to drive metastasis. Cancer Res 72: 4130-4140, 2012.
6. Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Rev Cancer 7: 763-777, 2007.
7. Kahajda FP: Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology. Nutrition 16: 202-208, 2000.
8. Puig T, Vázquez-Martín A, Relat J, Pitré J, Menéndez JA, Porta R, Casals G, Marrero PF, Haro D, Brunet J and Colomer R: Fatty acid metabolism in breast cancer cells: Differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat 109: 471-479, 2008.
9. Nakakuki M, Shimano H, Ioue N, Tamura M, Matsuzaka T, Nakagawa Y, Yahagi N, Toyoshima H, Sato R and Yamada N: A transcription factor of lipid synthesis, sterol regulatory element-binding protein (SREBP)-1 causes G1 cell-cycle arrest after accumulation of cyclin-dependent kinase (cdk) inhibitors. FEBS J 274: 4440-4452, 2007.
10. Taskinen MR: Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia 46: 733-749, 2003.
11. Ruiz R, Jideonwovu V, Ahm M, Surendran S, Tagliabracci VS, Hou Y, Gambale A, Kerner I, Irimia-Dominguez JM, Puchowicz et al: Sterol regulatory element-binding protein-1 (SREBP-1) is required to regulate glycerogen synthesis and gluconeogenic gene expression in mouse liver. J Biol Chem 289: 5510-5517, 2014.
12. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, et al: EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2: ra82, 2009.
13. Porstmann T, Griffiths B, Chung YL, Delpeuch O, Griffiths JR, Downward J and Schulze A: PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24: 6465-6481, 2005.
14. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, Gorgun C, Kwiatkowski DJ, Hotamisligil GS, Lee CH and Manning BD: Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 14: 21-32, 2011.
15. Nie LY, Lu QT, Li WH, Yang N, Dongol S, Zhang X and Jiang S: Sterol regulatory element-binding protein 1 is required for ovarian tumor growth. Oncol Rep 30: 1346-1354, 2013.
16. Guo D, Bell EH and Chakravarti A: Lipid metabolism emerges as a promising target for malignant glioma therapy. CNS Oncol 2: 289-299, 2013.
17. Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T, Zhong Z, McCua PA, Sang N, Ji YJ, et al: Repression of endometrial tumor growth by targeting SREBP1c and lipogenesis. Cell Cycle 11: 2348-2358, 2012.
18. Huang WC, Li X, Liu J, Lin J and Chung LW: Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res 10: 133-142, 2012.
19. Miyachi K, Sawada Y, Shida Y, Sugawara A and Hisatomi H: Lipogenic gene expression profile in patients with gastric cancer. Mol Clin Oncol 1: 825-827, 2013.
20. Mashima T, Seimiya H and Tsuruo T: De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 100: 1369-1372, 2009.
21. Ameer F, Scanduzzi L, Hasnain S, Kalbacher H and Zaidi N: De novo lipogenesis in health and disease. Metabolism 63: 895-902, 2014.
22. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Desteﬁn G, Delouso S, Zimmermann A, Ericsson J, et al: Increased lipogenesis, induced by AKT-mTORC1-PS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterol teraology 140: 1071-1083, 2011.
23. Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T and Kaneko S: Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol 50: 110-119, 2009.
24. Swinnen JVN, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W and Verhoeven G: Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 92: 273-279, 2004.
25. Song HJ, Sneddon AA, Heys SD and Wahle KW: Regulation of fatty acid synthase (FAS) and apoptosis in estrogen-receptor-positive and negative breast cancer cells by conjugated linoleic acids. Prostaglandins Leukot Essent Fatty Acids 79: 197-203, 2012.
26. Lee JS, Sul JY, Park JB, Lee MS, Cha EY, Song IS, Kim JR and Chang ES: Fatty acid synthase inhibition by aminothiazole suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells. Phyther Res 27: 713-720, 2013.
27. Roongta UV, Fábalan JG, Wang X, Ryseck RP, Fargnoli J, Henley BJ, Yang WP, Zhu J, Madiredhi MT, Lawrence RM, et al: Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res 9: 1531-1542, 2011.
28. Tong L and Harwood HJ Jr: Acetyl-coenzyme A carboxylases: Versatile targets for drug discovery. J Cell Biochem 99: 4746-4848, 2006.